NCT05967416 is a Phase 1 clinical trial of SIRPant-M in Refractory Non-Hodgkin Lymphoma, sponsored by SIRPant Immunotherapeutics, Inc..

Who is sponsoring NCT05967416?

NCT05967416 is sponsored by SIRPant Immunotherapeutics, Inc..

What drugs are being tested in NCT05967416?

Interventions in NCT05967416: SIRPant-M, External-beam radiotherapy (XRT).

What condition does NCT05967416 study?

NCT05967416 studies Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma.

Is NCT05967416 still recruiting?

NCT05967416 is currently recruiting now. Last updated 17 December 2024.

Last reviewed 2024-12-17 · How we verify

NCT05967416

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Study of Autologous SIRPα-low Macrophages (SIRPant-M) Administered by IT- Injection Alone or in Combination With Focal External-Beam Radiotherapy in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting now Phase 1 Last updated 17 December 2024

What this trial tests

Phase 1 trial testing SIRPant-M in Refractory Non-Hodgkin Lymphoma in 24 participants. Currently enrolling.

Timeline

17 January 2024

Primary endpoint
1 June 2025

1 December 2025

Quick facts

Lead sponsor	SIRPant Immunotherapeutics, Inc.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	17 January 2024
Primary completion	1 June 2025
Estimated completion	1 December 2025
Sites	3 locations across United States

Drugs / interventions tested

SIRPant-M — full drug profile →
External-beam radiotherapy (XRT)

Conditions studied

Refractory Non-Hodgkin Lymphoma — all drugs for Refractory Non-Hodgkin Lymphoma →
Relapsed Non-Hodgkin Lymphoma — all drugs for Relapsed Non-Hodgkin Lymphoma →

Sponsor

SIRPant Immunotherapeutics, Inc. — full company profile →

Who can join

18 and older, any sex, with Refractory Non-Hodgkin Lymphoma or Relapsed Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Incidence of treatment emergent adverse events (TEAEs) and adverse events (AEs)
Time frame: Day -42 through Day 364
Includes evaluation of frequency and severity of AEs, serious adverse events (SAEs), TEAEs, and adverse events of special interest (AESIs), including injection site reactions and abnormalities in clinical laboratory assessments, vital signs, or physical examination findings. Graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

Sponsor's own description

The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cell-Based Therapies for Solid Tumors: Challenges and Advances.
Smolarska A, Kokoszka Z, Naliwajko M, Strupczewska J, et al · · 2025 · cited 4× · PMID 40564987 · DOI 10.3390/ijms26125524
Incorporating Immunotherapy with Radiotherapy for Lymphomas.
Strati P, Spiotto MT. · · 2023 · cited 2× · PMID 39917366 · DOI 10.3390/lymphatics1030018
Roles of the phagocytosis checkpoint in radiotherapy.
Kui Y, Tong F, Zhang R, Wang J, et al · · 2025 · PMID 40835598 · DOI 10.1038/s41419-025-07921-5

Verify or expand the search:

Other recruiting trials for Refractory Non-Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07166419 — Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory N · Phase 1 · recruiting
NCT05077527 — Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · Phase 1 · recruiting
NCT06550141 — Emapalumab Prevention of CAR-T Cell Associated Toxicities · Phase 2 · recruiting
NCT06343311 — T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · Phase 1, PHASE2 · recruiting
NCT06026319 — CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05967416 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SIRPant Immunotherapeutics, Inc.
Last refreshed: 17 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05967416.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing